nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—ABCB1—Dactinomycin—muscle cancer	0.155	0.197	CbGbCtD
Levomilnacipran—CYP2C8—Etoposide—muscle cancer	0.129	0.164	CbGbCtD
Levomilnacipran—ABCB1—Vincristine—muscle cancer	0.0956	0.121	CbGbCtD
Levomilnacipran—ABCB1—Etoposide—muscle cancer	0.0876	0.111	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—muscle cancer	0.0597	0.0759	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—muscle cancer	0.0579	0.0735	CbGbCtD
Levomilnacipran—CYP3A4—Vincristine—muscle cancer	0.0573	0.0727	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—muscle cancer	0.0563	0.0715	CbGbCtD
Levomilnacipran—CYP3A4—Etoposide—muscle cancer	0.0525	0.0667	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—muscle cancer	0.0358	0.0455	CbGbCtD
Levomilnacipran—Erythema multiforme—Dactinomycin—muscle cancer	0.0016	0.0075	CcSEcCtD
Levomilnacipran—Flushing—Dactinomycin—muscle cancer	0.00157	0.00736	CcSEcCtD
Levomilnacipran—Chills—Dactinomycin—muscle cancer	0.00151	0.00712	CcSEcCtD
Levomilnacipran—Hallucination—Vincristine—muscle cancer	0.0015	0.00705	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Vincristine—muscle cancer	0.0015	0.00705	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Vincristine—muscle cancer	0.00149	0.007	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Vincristine—muscle cancer	0.00148	0.00696	CcSEcCtD
Levomilnacipran—Urethral disorder—Vincristine—muscle cancer	0.00148	0.00695	CcSEcCtD
Levomilnacipran—Delirium—Doxorubicin—muscle cancer	0.00147	0.00689	CcSEcCtD
Levomilnacipran—Neutropenia—Etoposide—muscle cancer	0.00143	0.00671	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Methotrexate—muscle cancer	0.00142	0.00669	CcSEcCtD
Levomilnacipran—Cystitis—Methotrexate—muscle cancer	0.00141	0.00661	CcSEcCtD
Levomilnacipran—Cardiac disorder—Vincristine—muscle cancer	0.0014	0.00658	CcSEcCtD
Levomilnacipran—Ventricular extrasystoles—Doxorubicin—muscle cancer	0.0014	0.00656	CcSEcCtD
Levomilnacipran—Angiopathy—Vincristine—muscle cancer	0.00137	0.00643	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Vincristine—muscle cancer	0.00136	0.00639	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00135	0.00634	CcSEcCtD
Levomilnacipran—Mental disorder—Vincristine—muscle cancer	0.00132	0.00621	CcSEcCtD
Levomilnacipran—Bladder pain—Methotrexate—muscle cancer	0.00132	0.00619	CcSEcCtD
Levomilnacipran—Leukopenia—Dactinomycin—muscle cancer	0.00131	0.00618	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Etoposide—muscle cancer	0.00129	0.00605	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Doxorubicin—muscle cancer	0.00123	0.00579	CcSEcCtD
Levomilnacipran—Cystitis—Doxorubicin—muscle cancer	0.00122	0.00573	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Etoposide—muscle cancer	0.00121	0.00571	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Etoposide—muscle cancer	0.00121	0.00567	CcSEcCtD
Levomilnacipran—Agitation—Vincristine—muscle cancer	0.00121	0.00567	CcSEcCtD
Levomilnacipran—Urethral disorder—Etoposide—muscle cancer	0.0012	0.00563	CcSEcCtD
Levomilnacipran—Infection—Dactinomycin—muscle cancer	0.00119	0.0056	CcSEcCtD
Levomilnacipran—Leukopenia—Vincristine—muscle cancer	0.00117	0.00552	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Dactinomycin—muscle cancer	0.00117	0.00552	CcSEcCtD
Levomilnacipran—Dry eye—Doxorubicin—muscle cancer	0.00116	0.00548	CcSEcCtD
Levomilnacipran—Erythema multiforme—Etoposide—muscle cancer	0.00115	0.00543	CcSEcCtD
Levomilnacipran—Renal failure acute—Methotrexate—muscle cancer	0.00115	0.00538	CcSEcCtD
Levomilnacipran—Anorexia—Dactinomycin—muscle cancer	0.00114	0.00537	CcSEcCtD
Levomilnacipran—Eye disorder—Etoposide—muscle cancer	0.00114	0.00536	CcSEcCtD
Levomilnacipran—Bladder pain—Doxorubicin—muscle cancer	0.00114	0.00536	CcSEcCtD
Levomilnacipran—Convulsion—Vincristine—muscle cancer	0.00114	0.00535	CcSEcCtD
Levomilnacipran—Flushing—Etoposide—muscle cancer	0.00113	0.00533	CcSEcCtD
Levomilnacipran—Cardiac disorder—Etoposide—muscle cancer	0.00113	0.00533	CcSEcCtD
Levomilnacipran—Hypertension—Vincristine—muscle cancer	0.00113	0.00533	CcSEcCtD
Levomilnacipran—Angiopathy—Etoposide—muscle cancer	0.00111	0.00521	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Etoposide—muscle cancer	0.0011	0.00517	CcSEcCtD
Levomilnacipran—Chills—Etoposide—muscle cancer	0.0011	0.00515	CcSEcCtD
Levomilnacipran—Infection—Vincristine—muscle cancer	0.00106	0.005	CcSEcCtD
Levomilnacipran—Nervous system disorder—Vincristine—muscle cancer	0.00105	0.00494	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Vincristine—muscle cancer	0.00105	0.00493	CcSEcCtD
Levomilnacipran—Decreased appetite—Dactinomycin—muscle cancer	0.00104	0.0049	CcSEcCtD
Levomilnacipran—Dysgeusia—Etoposide—muscle cancer	0.00104	0.00489	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Vincristine—muscle cancer	0.00104	0.00487	CcSEcCtD
Levomilnacipran—Fatigue—Dactinomycin—muscle cancer	0.00103	0.00486	CcSEcCtD
Levomilnacipran—Anorexia—Vincristine—muscle cancer	0.00102	0.0048	CcSEcCtD
Levomilnacipran—Irritability—Methotrexate—muscle cancer	0.00101	0.00474	CcSEcCtD
Levomilnacipran—Hypotension—Vincristine—muscle cancer	0.001	0.0047	CcSEcCtD
Levomilnacipran—Renal failure acute—Doxorubicin—muscle cancer	0.000992	0.00466	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00098	0.00461	CcSEcCtD
Levomilnacipran—Hot flush—Doxorubicin—muscle cancer	0.000979	0.0046	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Methotrexate—muscle cancer	0.000976	0.00459	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Doxorubicin—muscle cancer	0.00097	0.00456	CcSEcCtD
Levomilnacipran—Insomnia—Vincristine—muscle cancer	0.000969	0.00455	CcSEcCtD
Levomilnacipran—Paraesthesia—Vincristine—muscle cancer	0.000962	0.00452	CcSEcCtD
Levomilnacipran—Breast disorder—Methotrexate—muscle cancer	0.000955	0.00449	CcSEcCtD
Levomilnacipran—Leukopenia—Etoposide—muscle cancer	0.000951	0.00447	CcSEcCtD
Levomilnacipran—Body temperature increased—Dactinomycin—muscle cancer	0.000948	0.00445	CcSEcCtD
Levomilnacipran—Abdominal pain—Dactinomycin—muscle cancer	0.000948	0.00445	CcSEcCtD
Levomilnacipran—Loss of consciousness—Etoposide—muscle cancer	0.000934	0.00439	CcSEcCtD
Levomilnacipran—Decreased appetite—Vincristine—muscle cancer	0.000931	0.00438	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Vincristine—muscle cancer	0.000925	0.00435	CcSEcCtD
Levomilnacipran—Fatigue—Vincristine—muscle cancer	0.000923	0.00434	CcSEcCtD
Levomilnacipran—Convulsion—Etoposide—muscle cancer	0.000921	0.00433	CcSEcCtD
Levomilnacipran—Hyponatraemia—Doxorubicin—muscle cancer	0.000919	0.00432	CcSEcCtD
Levomilnacipran—Hypertension—Etoposide—muscle cancer	0.000918	0.00431	CcSEcCtD
Levomilnacipran—Constipation—Vincristine—muscle cancer	0.000916	0.00431	CcSEcCtD
Levomilnacipran—Chest pain—Etoposide—muscle cancer	0.000905	0.00425	CcSEcCtD
Levomilnacipran—Migraine—Doxorubicin—muscle cancer	0.000901	0.00424	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000899	0.00423	CcSEcCtD
Levomilnacipran—Hypersensitivity—Dactinomycin—muscle cancer	0.000883	0.00415	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Vincristine—muscle cancer	0.000876	0.00412	CcSEcCtD
Levomilnacipran—Infection—Etoposide—muscle cancer	0.000862	0.00405	CcSEcCtD
Levomilnacipran—Asthenia—Dactinomycin—muscle cancer	0.00086	0.00404	CcSEcCtD
Levomilnacipran—Dysuria—Methotrexate—muscle cancer	0.000854	0.00402	CcSEcCtD
Levomilnacipran—Neutropenia—Methotrexate—muscle cancer	0.000854	0.00402	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Etoposide—muscle cancer	0.000849	0.00399	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000849	0.00399	CcSEcCtD
Levomilnacipran—Tachycardia—Etoposide—muscle cancer	0.000847	0.00398	CcSEcCtD
Levomilnacipran—Abdominal pain—Vincristine—muscle cancer	0.000847	0.00398	CcSEcCtD
Levomilnacipran—Body temperature increased—Vincristine—muscle cancer	0.000847	0.00398	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Doxorubicin—muscle cancer	0.000845	0.00397	CcSEcCtD
Levomilnacipran—Skin disorder—Etoposide—muscle cancer	0.000843	0.00396	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Methotrexate—muscle cancer	0.000842	0.00396	CcSEcCtD
Levomilnacipran—Dry skin—Doxorubicin—muscle cancer	0.000839	0.00395	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Etoposide—muscle cancer	0.000839	0.00394	CcSEcCtD
Levomilnacipran—Breast disorder—Doxorubicin—muscle cancer	0.000827	0.00389	CcSEcCtD
Levomilnacipran—Anorexia—Etoposide—muscle cancer	0.000827	0.00389	CcSEcCtD
Levomilnacipran—Diarrhoea—Dactinomycin—muscle cancer	0.00082	0.00386	CcSEcCtD
Levomilnacipran—Hypotension—Etoposide—muscle cancer	0.000811	0.00381	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000808	0.0038	CcSEcCtD
Levomilnacipran—Abdominal distension—Doxorubicin—muscle cancer	0.000797	0.00374	CcSEcCtD
Levomilnacipran—Hypersensitivity—Vincristine—muscle cancer	0.000789	0.00371	CcSEcCtD
Levomilnacipran—Paraesthesia—Etoposide—muscle cancer	0.000779	0.00366	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—muscle cancer	0.000777	0.00365	CcSEcCtD
Levomilnacipran—Dyspnoea—Etoposide—muscle cancer	0.000773	0.00364	CcSEcCtD
Levomilnacipran—Somnolence—Etoposide—muscle cancer	0.000771	0.00363	CcSEcCtD
Levomilnacipran—Angina pectoris—Doxorubicin—muscle cancer	0.000771	0.00362	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—muscle cancer	0.000771	0.00362	CcSEcCtD
Levomilnacipran—Asthenia—Vincristine—muscle cancer	0.000768	0.00361	CcSEcCtD
Levomilnacipran—Vomiting—Dactinomycin—muscle cancer	0.000762	0.00358	CcSEcCtD
Levomilnacipran—Rash—Dactinomycin—muscle cancer	0.000756	0.00355	CcSEcCtD
Levomilnacipran—Decreased appetite—Etoposide—muscle cancer	0.000754	0.00355	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Etoposide—muscle cancer	0.000749	0.00352	CcSEcCtD
Levomilnacipran—Fatigue—Etoposide—muscle cancer	0.000748	0.00352	CcSEcCtD
Levomilnacipran—Constipation—Etoposide—muscle cancer	0.000742	0.00349	CcSEcCtD
Levomilnacipran—Neutropenia—Doxorubicin—muscle cancer	0.00074	0.00348	CcSEcCtD
Levomilnacipran—Dysuria—Doxorubicin—muscle cancer	0.00074	0.00348	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000735	0.00346	CcSEcCtD
Levomilnacipran—Diarrhoea—Vincristine—muscle cancer	0.000733	0.00344	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—muscle cancer	0.000731	0.00344	CcSEcCtD
Levomilnacipran—Pollakiuria—Doxorubicin—muscle cancer	0.000731	0.00344	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Methotrexate—muscle cancer	0.000722	0.0034	CcSEcCtD
Levomilnacipran—Urethral disorder—Methotrexate—muscle cancer	0.000717	0.00337	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—muscle cancer	0.000716	0.00337	CcSEcCtD
Levomilnacipran—Nausea—Dactinomycin—muscle cancer	0.000712	0.00335	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Etoposide—muscle cancer	0.000709	0.00334	CcSEcCtD
Levomilnacipran—Dizziness—Vincristine—muscle cancer	0.000708	0.00333	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000699	0.00329	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—muscle cancer	0.000692	0.00325	CcSEcCtD
Levomilnacipran—Urticaria—Etoposide—muscle cancer	0.000689	0.00324	CcSEcCtD
Levomilnacipran—Abdominal pain—Etoposide—muscle cancer	0.000686	0.00322	CcSEcCtD
Levomilnacipran—Body temperature increased—Etoposide—muscle cancer	0.000686	0.00322	CcSEcCtD
Levomilnacipran—Urinary tract infection—Doxorubicin—muscle cancer	0.000686	0.00322	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—muscle cancer	0.000683	0.00321	CcSEcCtD
Levomilnacipran—Vomiting—Vincristine—muscle cancer	0.000681	0.0032	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—muscle cancer	0.000679	0.00319	CcSEcCtD
Levomilnacipran—Rash—Vincristine—muscle cancer	0.000675	0.00317	CcSEcCtD
Levomilnacipran—Dermatitis—Vincristine—muscle cancer	0.000675	0.00317	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—muscle cancer	0.000673	0.00316	CcSEcCtD
Levomilnacipran—Headache—Vincristine—muscle cancer	0.000671	0.00315	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000667	0.00314	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—muscle cancer	0.000664	0.00312	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—muscle cancer	0.000659	0.0031	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—muscle cancer	0.000656	0.00309	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—muscle cancer	0.000641	0.00301	CcSEcCtD
Levomilnacipran—Hypersensitivity—Etoposide—muscle cancer	0.000639	0.003	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—muscle cancer	0.000637	0.00299	CcSEcCtD
Levomilnacipran—Nausea—Vincristine—muscle cancer	0.000636	0.00299	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—muscle cancer	0.000633	0.00298	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—muscle cancer	0.00063	0.00296	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—muscle cancer	0.000625	0.00294	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—muscle cancer	0.000624	0.00293	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—muscle cancer	0.000623	0.00293	CcSEcCtD
Levomilnacipran—Asthenia—Etoposide—muscle cancer	0.000622	0.00293	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—muscle cancer	0.000622	0.00293	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—muscle cancer	0.000621	0.00292	CcSEcCtD
Levomilnacipran—Pruritus—Etoposide—muscle cancer	0.000614	0.00289	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—muscle cancer	0.0006	0.00282	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—muscle cancer	0.000599	0.00282	CcSEcCtD
Levomilnacipran—Diarrhoea—Etoposide—muscle cancer	0.000594	0.00279	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—muscle cancer	0.000592	0.00278	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—muscle cancer	0.000588	0.00276	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—muscle cancer	0.000588	0.00276	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—muscle cancer	0.000575	0.0027	CcSEcCtD
Levomilnacipran—Dizziness—Etoposide—muscle cancer	0.000574	0.0027	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—muscle cancer	0.000571	0.00268	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—muscle cancer	0.00057	0.00268	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—muscle cancer	0.000568	0.00267	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—muscle cancer	0.000555	0.00261	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—muscle cancer	0.000552	0.00259	CcSEcCtD
Levomilnacipran—Vomiting—Etoposide—muscle cancer	0.000552	0.00259	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—muscle cancer	0.000551	0.00259	CcSEcCtD
Levomilnacipran—Rash—Etoposide—muscle cancer	0.000547	0.00257	CcSEcCtD
Levomilnacipran—Dermatitis—Etoposide—muscle cancer	0.000546	0.00257	CcSEcCtD
Levomilnacipran—Headache—Etoposide—muscle cancer	0.000543	0.00256	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—muscle cancer	0.000543	0.00255	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—muscle cancer	0.000542	0.00255	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—muscle cancer	0.000541	0.00254	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—muscle cancer	0.00054	0.00254	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000538	0.00253	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—muscle cancer	0.00052	0.00244	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—muscle cancer	0.000516	0.00243	CcSEcCtD
Levomilnacipran—Nausea—Etoposide—muscle cancer	0.000515	0.00242	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—muscle cancer	0.00051	0.0024	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—muscle cancer	0.000509	0.00239	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—muscle cancer	0.000507	0.00238	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—muscle cancer	0.000505	0.00237	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—muscle cancer	0.000502	0.00236	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—muscle cancer	0.000495	0.00233	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—muscle cancer	0.000494	0.00232	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—muscle cancer	0.000493	0.00232	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—muscle cancer	0.000487	0.00229	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—muscle cancer	0.000486	0.00228	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—muscle cancer	0.000485	0.00228	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—muscle cancer	0.000478	0.00225	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—muscle cancer	0.000476	0.00224	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—muscle cancer	0.00047	0.00221	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—muscle cancer	0.000469	0.00221	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—muscle cancer	0.000468	0.0022	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—muscle cancer	0.000467	0.00219	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000466	0.00219	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—muscle cancer	0.000463	0.00218	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—muscle cancer	0.000462	0.00217	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—muscle cancer	0.000459	0.00216	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—muscle cancer	0.000457	0.00215	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—muscle cancer	0.000452	0.00212	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000449	0.00211	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—muscle cancer	0.000448	0.00211	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—muscle cancer	0.000447	0.0021	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—muscle cancer	0.000443	0.00208	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—muscle cancer	0.000441	0.00207	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—muscle cancer	0.000441	0.00207	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—muscle cancer	0.000439	0.00206	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—muscle cancer	0.000437	0.00205	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—muscle cancer	0.000435	0.00204	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—muscle cancer	0.000429	0.00202	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—muscle cancer	0.000425	0.002	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—muscle cancer	0.00042	0.00198	CcSEcCtD
Levomilnacipran—Urticaria—Methotrexate—muscle cancer	0.000413	0.00194	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—muscle cancer	0.000411	0.00193	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—muscle cancer	0.000411	0.00193	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—muscle cancer	0.000407	0.00191	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—muscle cancer	0.000404	0.0019	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—muscle cancer	0.000401	0.00189	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—muscle cancer	0.0004	0.00188	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—muscle cancer	0.000396	0.00186	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—muscle cancer	0.000391	0.00184	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000388	0.00183	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—muscle cancer	0.000388	0.00182	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—muscle cancer	0.000385	0.00181	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—muscle cancer	0.000383	0.0018	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—muscle cancer	0.000373	0.00175	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000368	0.00173	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—muscle cancer	0.000368	0.00173	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—muscle cancer	0.000357	0.00168	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—muscle cancer	0.000356	0.00167	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—muscle cancer	0.000356	0.00167	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—muscle cancer	0.000356	0.00167	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—muscle cancer	0.000344	0.00162	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—muscle cancer	0.000331	0.00156	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—muscle cancer	0.00033	0.00155	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—muscle cancer	0.000328	0.00154	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—muscle cancer	0.000327	0.00154	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—muscle cancer	0.000326	0.00153	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—muscle cancer	0.000323	0.00152	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—muscle cancer	0.000318	0.0015	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—muscle cancer	0.000309	0.00145	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—muscle cancer	0.000308	0.00145	CcSEcCtD
Levomilnacipran—Dizziness—Doxorubicin—muscle cancer	0.000298	0.0014	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—muscle cancer	0.000286	0.00134	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—muscle cancer	0.000284	0.00133	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—muscle cancer	0.000283	0.00133	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—muscle cancer	0.000282	0.00133	CcSEcCtD
Levomilnacipran—Nausea—Doxorubicin—muscle cancer	0.000267	0.00126	CcSEcCtD
